百诚医药：全资子公司申报的BIOS2242口服溶液获得临床试验批准通知书

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Saimo Pharmaceutical, has received clinical trial approval from the National Medical Products Administration (NMPA) for the drug BIOS2242 oral solution, which is intended for the treatment of mild to moderate acute ischemic stroke [1] Group 1 - The drug BIOS2242 oral solution is specifically designed for treating mild to moderate acute ischemic stroke [1]